LONDON - Big pharma has publicly embraced gene therapy for the first time, with the signing of a $690 million deal between Sanofi-Aventis SA and Oxford BioMedica plc for TroVax. (BioWorld International)
Algeta ASA's IPO on the Oslo Stock Exchange hit the upper end of its target, raising gross proceeds of slightly less than NOK250 million (US$41.1 million). (BioWorld International)
RSS